Ikarian Capital’s Aclaris Therapeutics ACRS Stock Holding History

Ikarian Capital’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-150,900	Closed	-$231K	–	136
2025 Q1	$231K	Sell	150,900 -199,100	-57%	-$425K	0.03%	135
2024 Q4	$868K	Buy	+350,000	New	+$871K	0.12%	113
2024 Q1	–	Sell	-19,482	Closed	-$20.5K	–	139
2023 Q4	$20.5K	Buy	+19,482	New	+$59.4K	﹤0.01%	132
2023 Q3	–	Sell	-200,163	Closed	-$1.71M	–	141
2023 Q2	$2.08M	Sell	200,163 -100,000	-33%	-$905K	0.33%	63
2023 Q1	$2.43M	Buy	+300,163	New	+$3.81M	0.55%	54
2022 Q2	–	Sell	-12,124	Closed	-$208K	–	140
2022 Q1	$208K	Buy	12,124 +1,339	+12%	+$18.3K	0.03%	165
2021 Q4	$156K	Sell	10,785 -31,927	-75%	-$484K	0.02%	164
2021 Q3	$770K	Sell	42,712 -47,076	-52%	-$755K	0.05%	168
2021 Q2	$1.58M	Sell	89,788 -98,412	-52%	-$2.24M	0.13%	144
2021 Q1	$4.74M	Sell	188,200 -111,800	-37%	-$2.19M	0.16%	122
2020 Q4	$1.94M	Buy	+300,000	New	+$1.27M	0.09%	157

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ikarian Capital's ACRS Position: Q2 2025 in Review

Ikarian Capital sold out of Aclaris Therapeutics (ACRS) in Q2 2025, closing a stake of 150,900 shares — an estimated $231K sold.

Ikarian Capital first reported a position in ACRS in Q4 2020 and held it in 11 quarters. The position peaked at $4.74M in Q1 2021. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2025.

Ikarian Capital reported no remaining Aclaris Therapeutics position as of Q2 2025 after selling out during the quarter.
Ikarian Capital sold 150,900 Aclaris Therapeutics shares in Q2 2025, an estimated $231K.
Ikarian Capital first reported a position in Aclaris Therapeutics in Q4 2020 and held it in 11 quarters.
Ikarian Capital's Aclaris Therapeutics position peaked at $4.74M in Q1 2021.
96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2025.

Based on Ikarian Capital's 13F filing for Q2 2025, filed 14 Aug 2025.